Symetis: Well-Positioned Next-Generation TAVI Player
Now among the most promising of an emerging group of second-generation transcatheter aortic valve implantation (TAVI) companies, Symetis didn’t start out that way. It began as a cell therapy company, but its initial technology failed. On the verge of running out of money, CEO Jacques Essinger, PhD, engineered a change of direction that ultimately turned Symetis into a TAVI company with the kinds of advantages that may provide it with a competitive advantage.
Candid conversations with C-suite leaders.
More from Global Vision
BMS has launched a new cancer drug access program for low-to-middle income countries, focusing on addressing health inequities and widening accessibility.
- • By
Taylor Wessing investment partners share their thoughts about market trends, the surge in AI interest and the new UK government’s approach to the life sciences agenda.
- • By
The recent Women in Advanced Therapies Global event, delivered via an interactive 24-hour platform, hosted a number of biopharma speakers who drew on personal and industry-wide experiences, all aligned by a desire to break biases.
More from In Vivo
- • By
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
- • By
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.